Hillman Solutions Corp.

**Signal Note: Driehaus Capital – HLMN Position Initiation** Driehaus's $8.1M entry into Hillman Solutions (HLMN) is notable given the firm's biotech focus, though HLMN is primarily a fastener/hardware distributor with limited clinical pipeline relevance. This signal warrants scrutiny on whether Driehaus identifies overlooked value in HLMN's operations, supply chain positioning, or potential M&A dynamics rather than a biotech catalyst. Without disclosed pipeline catalysts or near-term clinical readouts in HLMN's portfolio, this appears driven by capital allocation/valuation thesis rather than imminent drug development milestones.